Send the following on WhatsApp
Continue to ChatThe First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China. https://www.vetrinatv.it/the-first-of-its-kind-in-the-world-the-recombinant-multivalent-covid-19-protein-vaccine-against-xbb-variants-by-westvac-biopharma-west-china-medical-center-sichuan-university-has-been-approved-for-c/